| Literature DB >> 28104566 |
Ricardo Costa1, Ami N Shah2, Cesar A Santa-Maria3, Marcelo R Cruz4, Devalingam Mahalingam5, Benedito A Carneiro3, Young Kwang Chae3, Massimo Cristofanilli3, William J Gradishar3, Francis J Giles3.
Abstract
Triple negative breast cancer (TNBC) accounts for 10-20% of cases in breast cancer. Despite recent advances in the treatment of hormonal receptor+ and HER2+ breast cancers, there are no targeted therapies available for TNBC. Evidence supports that most patients with TNBC express the transmembrane Epidermal Growth Factor Receptor (EGFR). However, early phase clinical trials failed to demonstrate significant activity of EGFR-targeted monoclonal antibodies and/or tyrosine kinase inhibitors. Here, we review the recent discoveries related to the underlying biology of the EGFR pathway in TNBC, clinical progress to date and suggest rational future approaches for investigational therapies in TNBC.Entities:
Keywords: Epidermal Growth Factor Receptor; Targeted therapy; Triple negative breast cancer; mTOR
Mesh：
Substances：
Year: 2017 PMID： 28104566 DOI： 10.1016/j.ctrv.2016.12.010
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111